Drug Discovery Symposium Spotlights Latest Cancer ResearchSept. 20, 2001
by Judy Long
Progress in the field of cancer research is the topic for the fall symposium of Baylor University's Center for Drug Discovery (CDD).
Two distinguished cancer researchers -- Dr. Klaus Edvardson, section head of tumor immunology at the University of Lund, Sweden, and Dr. Dai Chaplin, director of research for Oxigene Inc. -- will make presentations at the symposium at 4:30 p.m., Thursday, Sept. 27, on the fifth floor of the Cashion Academic Center in the Hankamer School of Business. Baylor faculty involved in cancer research will begin the meetings with descriptions of Baylor CDD cancer research programs at 4:30 p.m., followed by student sessions and dinner at 5:30 p.m.
From 6:30 to 8 p.m., Edvardson and Chaplin will speak on the latest developments in cancer chemotherapeutics. All members of the Baylor community and other interested parties are invited to attend.
The Center for Drug Discovery conducts a variety of drug development projects, including searching for agents that bind the protein tubulin, which causes cancer growth. Some of these agents are capable of cutting off blood flow to tumors, causing the tumor to die quickly.
For more information, contact Dr. Chris Kearney, associate director of the Center for Drug Discovery, at 710-6793.